A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Geographic Atrophy · Macular Degeneration
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2/3
- Patients
- 274 (planned)
- Started
- Sep 19, 2024
- Main results expected
- Aug 24, 2029
- Fully finished
- Jul 16, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Ocular and Systemic Treatment-emergent Adverse Events (TEAEs)
Measured over: Upto 5 Years
Number of Participants with Abnormal Findings in Clinical Laboratory Assessments
Measured over: Upto 5 Years
Number of Participants with Abnormal Findings in Retinal imaging and Eye Examinations
Measured over: Upto 5 Years
Change from Baseline in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score
Measured over: Baseline up to 42 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06635148 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC